See more : EarthRenew Inc. (ERTH.CN) Income Statement Analysis – Financial Results
Complete financial analysis of Senstar Technologies Ltd. (SNT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Senstar Technologies Ltd., a leading company in the Security & Protection Services industry within the Industrials sector.
You may be interested
- Sterling Bancorp (STL-PA) Income Statement Analysis – Financial Results
- Osiris Acquisition Corp. (OSI) Income Statement Analysis – Financial Results
- ENDRA Life Sciences Inc. (NDRA) Income Statement Analysis – Financial Results
- FGI Industries Ltd. (FGIWW) Income Statement Analysis – Financial Results
- Capitol Health Limited (CAJ.AX) Income Statement Analysis – Financial Results
Senstar Technologies Ltd. (SNT)
Industry: Security & Protection Services
Sector: Industrials
Website: https://www.senstartechnologies.com
About Senstar Technologies Ltd.
Senstar Technologies Ltd. develops, manufactures, markets, and sells perimeter intrusion detection sensors, physical barriers, video analytics and management systems, and security video observation and surveillance systems. The company offers Perimeter Intrusion Detection Systems (PIDS), fence mounted, buried, and free standing; PIDS fence sensor with intelligent perimeter LED based lighting; common operating platform for video management software, including intelligent video analytics applications, PIDS, and electronic access control systems; security thermal imaging observation and surveillance systems; and life safety or duress alarm systems. The company's products are used to protect borders and sensitive facilities, including military bases, power plants, air and sea ports, prisons, industrial sites, large retailer organizations, banks, and oil and gas facilities; sporting events, including athlete villages and stadiums, and municipalities from intrusion, terror, crime, sabotage or vandalism to infrastructure, assets and personnel. Senstar Technologies Ltd. sells its products through system integrators and distribution channels. The company was formerly known as Magal Security Systems Ltd. and changed its name to Senstar Technologies Ltd. in September 2021. Senstar Technologies Ltd. was incorporated in 1984 and is based in Ramat Gan, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 32.79M | 35.56M | 34.92M | 81.27M | 86.83M | 92.60M | 64.29M | 67.83M | 63.74M | 77.54M | 51.52M | 77.70M | 88.59M | 49.70M | 54.52M | 70.36M | 72.38M | 66.96M | 61.28M | 60.97M | 59.36M | 42.97M | 41.02M | 38.57M | 31.97M | 32.10M | 25.50M | 18.20M | 17.10M | 16.80M | 10.70M |
| Cost of Revenue | 13.94M | 14.06M | 12.94M | 46.71M | 48.07M | 52.30M | 32.97M | 34.57M | 32.72M | 43.05M | 31.06M | 44.16M | 49.09M | 31.40M | 33.33M | 49.21M | 43.51M | 40.23M | 39.15M | 33.73M | 33.38M | 23.92M | 21.51M | 20.52M | 15.26M | 15.20M | 12.00M | 9.90M | 8.80M | 8.50M | 5.50M |
| Gross Profit | 18.85M | 21.50M | 21.98M | 34.56M | 38.76M | 40.30M | 31.33M | 33.26M | 31.01M | 34.49M | 20.46M | 33.53M | 39.50M | 18.30M | 21.19M | 21.15M | 28.87M | 26.73M | 22.13M | 27.25M | 25.98M | 19.04M | 19.52M | 18.05M | 16.70M | 16.90M | 13.50M | 8.30M | 8.30M | 8.30M | 5.20M |
| Gross Profit Ratio | 57.48% | 60.47% | 62.95% | 42.52% | 44.64% | 43.52% | 48.72% | 49.03% | 48.66% | 44.48% | 39.71% | 43.16% | 44.59% | 36.82% | 38.86% | 30.06% | 39.88% | 39.92% | 36.11% | 44.69% | 43.77% | 44.32% | 47.57% | 46.79% | 52.25% | 52.65% | 52.94% | 45.60% | 48.54% | 49.40% | 48.60% |
| Research & Development | 4.01M | 4.03M | 3.93M | 5.66M | 6.37M | 6.85M | 6.56M | 6.78M | 4.81M | 4.60M | 4.41M | 4.04M | 3.90M | 4.11M | 4.82M | 6.20M | 5.76M | 5.38M | 5.27M | 4.68M | 4.77M | 3.13M | 3.05M | 2.98M | 2.68M | 2.30M | 2.00M | 2.00M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 6.15M | 6.98M | 6.97M | 9.71M | 9.45M | 11.14M | 7.85M | 7.45M | 7.03M | 8.90M | 7.79M | 7.41M | 8.68M | 7.59M | 8.22M | 13.47M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 9.95M | 9.01M | 10.00M | 13.83M | 16.90M | 18.56M | 18.16M | 17.54M | 14.79M | 17.13M | 12.78M | 16.53M | 19.42M | 11.26M | 10.88M | 17.18M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 16.11M | 15.99M | 16.97M | 23.54M | 26.35M | 29.70M | 26.01M | 24.98M | 21.81M | 26.03M | 20.57M | 23.94M | 28.10M | 18.85M | 19.09M | 30.65M | 20.40M | 18.61M | 19.14M | 18.45M | 16.89M | 13.58M | 12.88M | 11.79M | 9.92M | 10.40M | 8.20M | 4.20M | 6.30M | 5.70M | 3.70M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 20.11M | 20.02M | 20.90M | 29.20M | 32.72M | 36.55M | 32.57M | 31.76M | 26.63M | 30.63M | 24.98M | 27.98M | 29.69M | 22.96M | 23.91M | 36.84M | 26.10M | 23.99M | 24.41M | 24.33M | 21.66M | 16.71M | 15.94M | 14.77M | 14.03M | 14.10M | 12.30M | 6.80M | 6.90M | 6.30M | 4.20M |
| Cost & Expenses | 34.06M | 34.07M | 33.84M | 75.91M | 80.79M | 88.85M | 65.54M | 66.33M | 59.35M | 73.68M | 56.04M | 72.14M | 78.78M | 54.36M | 57.24M | 86.05M | 69.61M | 64.22M | 63.56M | 58.06M | 55.04M | 40.63M | 37.44M | 35.29M | 29.29M | 29.30M | 24.30M | 16.70M | 15.70M | 14.80M | 9.70M |
| Interest Income | 151.00K | 48.00K | 26.00K | 158.00K | 664.00K | 670.00K | 462.00K | 303.00K | 54.00K | 141.00K | 337.00K | 671.00K | 1.91M | 182.00K | 484.00K | 864.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 157.00K | 273.00K | 52.00K | 310.00K | 360.00K | 412.00K | 349.00K | 299.00K | 381.00K | 493.00K | 406.00K | 602.00K | 1.16M | 967.00K | 1.57M | 2.01M | 1.90M | 1.39M | 1.25M | 1.30M | 1.11M | 0.00 | 942.00K | 214.00K | 0.00 | 900.00K | 0.00 | 200.00K | 100.00K | 300.00K | 200.00K |
| Depreciation & Amortization | 917.00K | 1.43M | 1.87M | 1.96M | 2.10M | 2.25M | 1.88M | 1.74M | 1.50M | 1.97M | 1.72M | 1.18M | 1.22M | 1.06M | 1.20M | 3.06M | 2.14M | 2.21M | 2.40M | 2.15M | 1.40M | 1.11M | 1.43M | 1.38M | 1.43M | 1.40M | 2.10M | 600.00K | 600.00K | 600.00K | 500.00K |
| EBITDA | -255.00K | 3.06M | 1.94M | 3.99M | 6.47M | 7.36M | -2.98M | 2.94M | 6.92M | 5.86M | -2.34M | 6.87M | 12.94M | -3.62M | -2.26M | -13.59M | 4.91M | 4.94M | 125.00K | 5.22M | 5.68M | 3.45M | 5.01M | 4.67M | 4.10M | 4.20M | 3.31M | 2.10M | 2.00M | 2.60M | 1.50M |
| EBITDA Ratio | -0.78% | 4.17% | 3.10% | 6.59% | 6.95% | 4.05% | 1.70% | 2.20% | 6.89% | 8.13% | -8.77% | 7.15% | 14.61% | -9.38% | -4.99% | -17.95% | 8.79% | 8.34% | 0.62% | 10.21% | 10.60% | 8.02% | 12.22% | 12.10% | 14.57% | 13.08% | 20.39% | 11.54% | 11.70% | 15.48% | 14.02% |
| Operating Income | -1.27M | 54.00K | -788.00K | 3.40M | 3.94M | 3.76M | -1.24M | 1.50M | 4.39M | 1.42M | -4.52M | 5.56M | 9.81M | -4.66M | -2.72M | -28.58M | 2.77M | 2.74M | -2.28M | 2.92M | 4.32M | 2.33M | 3.58M | 3.28M | 2.67M | 2.80M | 1.20M | 1.50M | 1.40M | 2.00M | 1.00M |
| Operating Income Ratio | -3.86% | 0.15% | -2.26% | 4.18% | 4.54% | 4.05% | -1.93% | 2.20% | 6.89% | 1.84% | -8.77% | 7.15% | 11.07% | -9.38% | -4.99% | -40.62% | 3.83% | 4.09% | -3.72% | 4.78% | 7.28% | 5.43% | 8.73% | 8.51% | 8.36% | 8.72% | 4.71% | 8.24% | 8.19% | 11.90% | 9.35% |
| Total Other Income/Expenses | -64.00K | 141.00K | -1.01M | -1.02M | 3.78M | 1.36M | -3.96M | -591.00K | 642.00K | -595.00K | 59.00K | -472.00K | 756.00K | -967.00K | -1.57M | -16.03M | -2.20M | -851.00K | -800.00K | -762.00K | -1.00M | 199.00K | 40.00K | -214.00K | -484.00K | -205.00K | -1.91M | -200.00K | -100.00K | 0.00 | -200.00K |
| Income Before Tax | -1.33M | 1.63M | 70.00K | 3.90M | 4.37M | 5.12M | -5.21M | 904.00K | 5.03M | 3.40M | -4.46M | 5.09M | 10.57M | -5.63M | -4.29M | -30.59M | 569.00K | 1.89M | -3.06M | 2.15M | 3.32M | 2.53M | 3.62M | 3.07M | 2.19M | 2.60M | -700.00K | 1.30M | 1.30M | 0.00 | 800.00K |
| Income Before Tax Ratio | -4.05% | 4.57% | 0.20% | 4.80% | 5.04% | 5.52% | -8.10% | 1.33% | 7.89% | 4.39% | -8.66% | 6.54% | 11.93% | -11.32% | -7.87% | -43.48% | 0.79% | 2.82% | -4.99% | 3.53% | 5.59% | 5.90% | 8.82% | 7.96% | 6.85% | 8.10% | -2.75% | 7.14% | 7.60% | 0.00% | 7.48% |
| Income Tax Expense | -40.00K | -2.40M | 2.26M | 3.00M | 1.55M | 2.07M | 1.70M | -122.00K | 1.92M | 82.00K | 69.00K | 991.00K | 723.00K | 602.00K | 728.00K | 1.62M | 373.00K | 948.00K | -23.00K | 1.10M | 913.00K | 645.00K | 452.00K | 180.00K | 259.00K | 300.00K | 200.00K | 100.00K | 200.00K | 300.00K | 200.00K |
| Net Income | -1.29M | 3.83M | -2.19M | 902.00K | 2.29M | 2.95M | -6.91M | 1.03M | 3.14M | 3.41M | -4.46M | 4.09M | 9.84M | -6.21M | -855.00K | -32.60M | 1.88M | 810.00K | -3.21M | 1.05M | 2.40M | 1.89M | 3.17M | 2.89M | 1.93M | 2.30M | -900.00K | 1.20M | 1.10M | 1.70M | 600.00K |
| Net Income Ratio | -3.93% | 10.77% | -6.28% | 1.11% | 2.64% | 3.18% | -10.75% | 1.52% | 4.93% | 4.40% | -8.66% | 5.27% | 11.11% | -12.49% | -1.57% | -46.34% | 2.60% | 1.21% | -5.24% | 1.73% | 4.05% | 4.39% | 7.72% | 7.49% | 6.04% | 7.17% | -3.53% | 6.59% | 6.43% | 10.12% | 5.61% |
| EPS | -0.06 | 0.16 | -0.09 | 0.04 | 0.10 | 0.13 | -0.30 | 0.06 | 0.18 | 0.20 | -0.26 | 0.25 | 0.74 | -0.56 | -0.08 | -2.96 | 0.17 | 0.08 | -0.30 | 0.11 | 0.27 | 0.21 | 0.36 | 0.31 | 0.21 | 0.25 | -0.10 | 0.19 | 0.16 | 0.25 | 0.10 |
| EPS Diluted | -0.06 | 0.16 | -0.09 | 0.04 | 0.10 | 0.13 | -0.30 | 0.06 | 0.18 | 0.20 | -0.26 | 0.25 | 0.74 | -0.56 | -0.08 | -2.96 | 0.17 | 0.08 | -0.30 | 0.11 | 0.27 | 0.20 | 0.36 | 0.31 | 0.21 | 0.25 | -0.10 | 0.19 | 0.16 | 0.25 | 0.10 |
| Weighted Avg Shares Out | 21.48M | 23.31M | 23.21M | 23.15M | 23.13M | 23.04M | 22.99M | 18.00M | 17.29M | 17.12M | 17.07M | 16.92M | 13.37M | 11.02M | 11.02M | 11.02M | 11.08M | 10.73M | 10.63M | 9.30M | 8.92M | 9.02M | 8.69M | 9.25M | 9.18M | 9.18M | 8.84M | 6.39M | 6.69M | 6.70M | 6.19M |
| Weighted Avg Shares Out (Dil) | 23.31M | 23.31M | 23.21M | 23.15M | 23.14M | 23.29M | 22.99M | 18.03M | 17.35M | 17.28M | 17.07M | 16.95M | 13.37M | 11.02M | 11.02M | 11.02M | 11.08M | 10.73M | 10.63M | 9.30M | 8.92M | 9.25M | 8.90M | 9.25M | 9.27M | 9.18M | 8.84M | 6.39M | 6.69M | 6.70M | 6.19M |
Senesco Technologies Receives Notice of Non-Compliance from NYSE MKT
BRIDGEWATER, N.J.--(BUSINESS WIRE)--On August 22, 2012, Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE MKT: SNT) received a notice from NYSE Regulation, Inc. on behalf of NYSE MKT LLC (the “NYSE MKT”) providing notification that NYSE MKT has determined not...
Senesco Announces that SNS01-T Showed Good Tolerability and Stable Disease in Newly Completed First Cohort of Phase 1b/2a Multiple Myeloma Trial
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE MKT: SNT) reported today that it has completed the first cohort of patients in its Phase 1b/2a clinical trial for the treatment of multiple myeloma in which SNS01-T was safe...
Senesco Announces Highly Statistically Significant Tumor Growth Inhibition by a Combination of Lenalidomide and SNS01-T in Cancer Model
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE MKT: SNT) announced today the results from the completed non-clinical study of SNS01-T in combination of lenalidomide in a model of multiple myeloma. Combining SNS01-T treatment with lenalidomide (the active...
Senesco’s Lead Therapeutic Candidate, SNS01-T, Granted Orphan Drug Status from FDA for Treatment of Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE MKT: SNT) reported today that it was informed on July 26th that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation for the company’s lead drug candidate SNS01-T...
Senesco Provides SNS01-T Update on Phase 1b/2a Multiple Myeloma Trial
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE MKT: SNT) reported today on the progress of its Phase 1b/2a study for the treatment of multiple myeloma, which is the subject of a poster presented today at the 2012...
Senesco’s SNS01-T to be Presented During Poster Session at 2012 Annual Meeting of the American Society of Clinical Oncology
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE MKT: SNT), announced today that a poster describing the ongoing SNS01-T study in multiple myeloma will be presented at the 2012 Annual Meeting of the American Society of Clinical Oncology,...
Senesco’s SNS01 is a Potent Regulator of Programmed Cell Death and Tumor Growth in Murine Models of Multiple Myeloma
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE MKT: SNT), announced today that the characteristics and activity of SNS01 have been released on-line in Molecular Therapy, the official journal of the American Society for Gene & Cell Therapy....
Senesco Technologies Reports Fiscal 2012 Third Quarter Results
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE Amex: SNT) today reported financial results for the third quarter of fiscal year 2012 which ended on March 31, 2012. Highlights of the third quarter and recent weeks include: Combination...
Senesco to Present SNS01-T, an eIF5A-based Nanoparticle in a Phase 1b/2a Trial to Treat Multiple Myeloma, is Effective in Models of B-Cell Lymphoma
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE Amex: SNT), announced today that an oral presentation will be delivered at the 15th Annual Meeting of the American Society of Gene & Cell Therapy. The conference will be held...
Combination of Lenalidomide and SNS01-T Effective in Cancer Model
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE AMEX: SNT) announced today that a high level of tumor eradication in a mouse model of human multiple myeloma was achieved with a combination of SNS01-T and lenalidomide. “SNS01-T has...
Source: https://incomestatements.info
Category: Stock Reports